The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase I trial of temsirolimus (TEM) plus sorafenib (SOR) in advanced hepatocellular carcinoma (HCC) with pharmacokinetic (PK) and biomarker correlates.
Robin Katie Kelley
No relevant relationships to disclose
Halla Sayed Nimeiri
No relevant relationships to disclose
Pamela N. Munster
No relevant relationships to disclose
Mary Frances Mulcahy
No relevant relationships to disclose
Maxwell Thomas Vergo
No relevant relationships to disclose
Amanda DeSon
No relevant relationships to disclose
Christi Murphy
No relevant relationships to disclose
Benjamin M. Yeh
No relevant relationships to disclose
Andrew H. Ko
No relevant relationships to disclose
Wolfgang Michael Korn
No relevant relationships to disclose
Jimmy Hwang
No relevant relationships to disclose
Madelyn Luttgen
No relevant relationships to disclose
Peter Kuhn
Consultant or Advisory Role - Epic Sciences
Stock Ownership - Epic Sciences
Yong Huang
No relevant relationships to disclose
Al Bowen Benson
Consultant or Advisory Role - Bayer
Research Funding - Bayer
Alan Paul Venook
Research Funding - Bayer; Onyx